VYGR - Voyager Therapeutics

-

$undefined

N/A

(N/A)

Voyager Therapeutics NasdaqGS:VYGR Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Location: 75 Hayden Avenue, Lexington, MA, 02421, United States | Website: https://www.voyagertherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-37.97M

Cash

236M

Avg Qtr Burn

-27.99M

Short % of Float

6.24%

Insider Ownership

16.59%

Institutional Own.

63.52%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AAV Capsids (Pfizer) Details
Neurological disorder

Phase 1

Update

AAV Capsids (Novartis) Details
Cardiovascular disease , Neurological disorder

Phase 1

Initiation

AAV Capsids Details
Cardiovascular disease , Neurological disorder

Phase 1

Initiation

Phase 1

Initiation

Phase 1a

Data readout

GBA1 gene therapy program Details
Parkinson's disease, Central nervous system illness

IND

Submission

VY-AADC (NBIb-1817) Details
Parkinson's disease, Central nervous system illness

Failed

Discontinued

VY9323 (SOD1 silencing gene therapy) Details
Neurodegenerative disease, Amyotrophic lateral sclerosis

Failed

Discontinued

VY-HTT01 Details
Huntington's disease

Failed

Discontinued